Overview

The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg

Status:
Unknown status

Trial end date:
2019-08-01

Target enrollment:

Participant gender:

Summary

HBeAg-negative chronic hepatitis B (CHB) patients with low Level HBsAg and with a history of drug resistance or suboptimal/partial virological response were enrolled. After giving informed consent, patients were treated with nucleoside analog(s) (NAs) once a day and weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week for 12 weeks. 12 weeks later, NAs was stopped, patients were treated with weekly subcutaneous injections of alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week. Treatment endpoint was HBsAg loss(<0.05 IU/mL).

Phase:

Phase 4

Details

Lead Sponsor:

Third Affiliated Hospital, Sun Yat-Sen University

Collaborators:

First People's Hospital of Foshan
First People's Hospital, Shunde China
Huazhong University of Science and Technology
Huizhou Municipal Central Hospital
Nanchang University
Peking University
Shenzhen Third People's Hospital
Tang-Du Hospital
The First Affiliated Hospital of Kunming Medical College
Yuebei People's Hospital

Treatments:

Interferon-alpha
Peginterferon alfa-2a
Peginterferon alfa-2b